Learn About OmegaBrite
High Quality Omega-3 Supplements
Our mission is to develop natural products of the highest quality that promote health and well being based on scientific evidence.
Eighteen years ago, OmegaBrite, set the gold standard for purity, concentration and scientific efficacy in omega-3s. We have continued to set the standard ever since.
While on faculty at Harvard Medical School, Dr. Locke formulated the first 90% high concentrate formula of pure omega-3, creating the first pharmaceutical grade high quality omega-3 supplement. Dr. Locke’s goal in creating OmegaBrite was simply to create the highest purity Omega 3 supplement based on science.
We were told what we wanted to create was too impractical, too expensive to make, too difficult to distill to such a high purity, high quality omega-3. But we stuck to our goal of creating the best omega-3 possible and brought to the world OmegaBrite, high concentrate, high EPA omega-3 with no after taste.
Our commitment to purity, safety and efficacy is the foundation of everything we do. We set the standard in omega-3 to bring you the very best from science and nature.
OmegaBrite was first formulated by Dr. Locke in 1998 while on faculty at Harvard Medical School. OmegaBrite is the leading provider of omega-3 and nutritional supplements based on the scientific evidence of efficacy of omega-3 fatty acids for improving cardiac health, emotional well-being, joint comfort, and overall health.
OmegaBrite received the Nutrition Business Journal’s Product Merit Award for creating the category of high concentrate Omega-3 supplements, bringing to the public the first high EPA omega-3 supplement, educating the public on the health benefits of EPA and omega-3s and raising the standards in the industry for purity and quality.
Exceeding all industry standards for purity and efficacy, OmegaBrite is ConsumerLabs approved. In reviews of pharmaceutical grade omega-3’s by ConsumerLabs and top universities, OmegaBrite tops the list.
In 1998 at Harvard Medical School, Dr. Locke set out to formulate the highest quality omega-3. Over seventeen years later OmegaBrite continues to raise the bar in purity, testing, and standards.
Formulation and Purity
OmegaBrite’s pharmaceutical quality omega-3 is manufactured using Good Manufacturing Processes (GMP) in a nitrogen environment, undergoing several molecular distillations to remove potential heavy metals or toxins (and therefore eliminate any aftertaste) and to obtain the maximum concentration of EPA and omega-3. OmegaBrite is continually manufactured using nitrogen to prevent the oxidation that occurs when omega-3s are exposed to the oxygen in the air. We only use small fish off the cold, clean waters of Peru and Chile to deliver the highest quality omega-3 on the market.
As a member of the Global Organization for EPA and DHA (GOED), OmegaBrite is a leader in the community and continues to raise the bar for third party testing procedures.
OmegaBrite was the first high concentrate omega-3 to introduce third party laboratory testing on every batch. Every batch of OmegaBrite has been tested before, during, and after production to ensure the highest quality omega-3 available.
OmegaBrite has also been independently tested by ConsumerLabs, winning their independent seal of approval by exceeding their highest standards for purity, potency, and accurate label claims.
At OmegaBrite we set the standard over eighteen years ago and we raise it every day.
Our commitment to excellence drives everything we do.
About Dr. Carol Locke, MD
Dr. Carol Locke is a practicing physician – Harvard educated and Harvard trained. Dr. Locke’s work focuses on an integrative evidence approach to improving people’s lives in both her practice and in her formulation of new natural products based on scientific evidence. Dr. Locke’s passion is helping people in her practice and in the development of new natural products to help her patients and the general public live better, longer, healthier lives.
Dr. Locke is a leader in educating both the medical community and the public on the health benefits of omega-3s. Deeply committed to promoting awareness of the health benefits of omega-3s around the world, Dr. Locke has spearheaded the creation and launch of the first International Omega-3 Awareness Day.
Carol Anne Locke, MD
University of California at Berkeley 1979-1982
1981-1982 President’s Undergraduate Fellowship
1981-1982 Honors Field Work Village Nataleira, Fiji Islands, The Meaning of Health
1982 Bachelors Degree Awarded in Anthropology, University of California at Berkeley
Highest Honors in Anthropology, Honors Thesis based on Field Work in Fiji “The Meaning of Health in a Fijian Village”
High Distinction in General Scholarship
Phi Beta Kappa
Harvard Medical School 1982-1986
1982 Harvard Medical School, Boston, MA
1983 National Academy of Science Summer Fellowship
1983 Research Harvard University, “Stressors in Local Hispanic Culture”.
1986 Doctor of Medicine Awarded, Harvard Medical School, Boston, MA.
Internship General Medicine 1986-1987
1986-1987 Internship in General Medicine Hackensack Hospital, New Jersey
Harvard Medical School McLean Hospital Adult Psychiatry Residency 1987-1990
1987-1990 Clinical Resident in Psychiatry Training Harvard Medical School, McLean
Hospital, Belmont Massachusetts, USA
1987-1990 Clinical Fellow
7/1990 Assistant Psychiatrist PIC SBII
1989-1990 Cognitive Behavioral Therapy Fellowship, Harvard Medical School, McLean Hospital, Belmont, MA.
1989-1990 Chief Resident in Mood Disorders Program, Harvard Medical School, McLean Hospital
1989-1990 American Psychiatric Association Mead-Johnson Fellowship Award
1990 Mel Chace Award for Leadership and Excellence in Practice
1990 Graduation Awarded Adult Psychiatry Residency Completion
1990 Board Certified in Psychiatry and Neurology
7/1990-11/2004 Clinical Instructor
2000 Assistant Professor Harvard Medical School
2000-2004 Associate Psychiatrist
2011 Women and Power: Leadership in a New World
Harvard Kennedy Schools program focus is on helping women advance to
top positions of influence in public leadership, across sectors, around the
Awards and Honors
1981 Phi Beta Kappa, University of California at Berkeley
1980 Torch and Shield Scholarship
1981 Pyrtanean Honor Society for Outstanding Women Scholars
1981 Clara and Claribel Farno Scholarship
1981 Phoebe A. Hearst Scholarship
1981 Eugene Wilson Scholarship
1982 Highest Honors in Anthropology
1982 High Distinction in General Scholarship
1983 Summer Fellow, National Institute of Medicine
1984 Sacramento Medical Society Scholarship
1989 American Psychiatric Association Mead-Johnson Fellowship
1990 Mel Kayce Award, McLean Hospital
2007 Product of Merit Award for OmegaBrite, Nutrition Business Journal
Fellowships and Postdoctoral Training
1979 President’s Undergraduate Fellowship, U.C. Berkeley
1983 National Academy of Science Summer Fellowship
1987-90 Resident in Adult Psychiatry, McLean Hospital, Belmont, MA
1989-90 American Psychiatric Association Mead Johnson Fellowship
1989-90 Cognitive Behavioral Therapy Fellowship, McLean Hospital
1989-90 Chief Resident, Affective Disorders Program, McLean Hospital
Licensure and Certification
1992-Present California Medical License
1988-1991 New Hampshire Medical License
1992-2005 Massachusetts Medical License
1987 DEA Registration Federal and State
1987 Diplomate, National Board of Medical Examiners
1992 Diplomate, American Board of Psychiatry and Neurology
1987-90 Clinical Fellow, Harvard Medical School, McLean Hospital Belmont MA
1989-1990 Chief Resident in Affective Disorders Program, McLean Hospital Belmont MA
1989-1990 Fellow in Cognitive Behavioral Medicine, McLean Hospital Belmont MA
1194-1998 Instructor in Psychiatry, McLean Hospital, McLean Hospital Belmont MA, Assistant Attending Psychiatrist McLean Hospital, Harvard Medical School
1998-2004 Associate Attending Psychiatrist, Harvard Medical School, McLean
Hospital Belmont MA
Hospital or Affiliated Institution Appointments During Residency
7/1987-6/90 Resident in Adult Psychiatry, McLean Hospital.
7/1989-6/90 Medical Staff Psychiatrist, Westwood Lodge, Westwood, MA
7/1988-6/91 Medical Staff Psychiatrist, Hampstead Hospital, NH
7/1988-6/90 Medical Staff Psychiatrist, Norwood Hospital, Brookline, MA.
7/1989-6/90 Chief Resident, Affective Disorders Program, McLean Hospital
Affiliated Institution Appointments After Graduation from Adult
Psychiatry Residency Graduation
7/1990-6/91 Psychiatrist-in-Charge on South Belknap II, an inpatient psychiatric unit
at McLean Hospital, Belmont MA
7/1990-6/98 Assistant Attending Psychiatrist, Harvard Medical School, McLean
Hospital, Belmont MA
7/1998-6/04 Associate Attending Psychiatrist, Harvard Medical School, McLean
Hospital, Belmont MA
Private Practice Adult Psychiatry McLean Hospital Harvard Medical School
7/1990-6/04 Private Practice McLean Hospital Attending’s Association
1981 Principal Investigator, Fiji Islands, University of California at Berkeley,
Department of Anthropology. Investigation of factors in the meaning of
health and choice of health care in a rural Fijian Village, as a Present’s
1983 Principal Investigator of a study examining the cultural Influences on the
bereavement process in three Boston Hispanic Communities, as a
Summer Fellow, National Institute of Medicine.
1989-90 Co-Principal Investigator on study of factors related to suicide.
1990 Co-Principal Investigator on the role of Prozac-associated
akathisia (motor restlessness) on suicidal behavior.
1998- Principal and Co-investigator on a series of clinical studies on
the role of omega-3 fatty acids in mood disorders.
Teaching and Speaking
1990-2000 Teaching medical students and psychiatry residents on elements of
1998-2011 Invited International speaker for Harvard Medical School on Continuing
Medical Education on Psychiatry and nutritional supplements and
complementary medicine. Dr. Larry Lifson
- Rothschild AS, Locke CA. Reexposure to fluoxetine after serious suicide
attempts by three patients: the role of akathisia. J Clin Psychiatry
- Rothschild AS, Locke CA: Reply to Letter to Editor. J Clin Psychiatry
- Stoll AL, Locke CA, Vuckovic A, Mayer PV. Lithium associated cognitive and
functional deficits reduced by a switch to divalproex sodium: A case series. J Clin
- Stoll AL, Locke CA, Marangell LB, Severus WE. Omega-3 fatty acids and bipolar
disorder: A review. Prostaglandins, Leukotrienes, and Essential Fatty Acids.
- Locke CA, Stoll AL. Omega-3 fatty acids in major depression. World Rev Nutr
- Locke CA, Rothschild A, Stoll AL, Murray M, Goldstein E. Completed suicides in
a psychiatric hospital: A controlled retrospective study. Abstracts of the First
Annual Harvard Medical School Research Day, Boston, 1993.
- Stoll AL, Locke CA. Omega-3 fatty acids in mood disorders: a review of
neurobiological and clinical actions. In Natural Medicines in Psychiatry (Eds: D
Mischoulon and J Rosenbaum). Wiley and Co. 2001.